PURE Bioscience Q3 sales rise to $506,000, loss steady
PURE Bioscience reported a rise in Q3 net product sales to $506,000 from $489,000 in the prior year, while the net loss remained steady at $(0.01) per share. For the nine months ended April 30, 2026, sales grew to $1,656,000 and the net loss narrowed to $1,873,000. The company announced CEO Jeff Kitchell will succeed Robert Bartlett in August 2026.
*this image is generated using AI for illustrative purposes only.
PURE Bioscience reported financial results for the fiscal third quarter ended April 30, 2026, highlighting a rise in net product sales and a steady net loss for the period. Net product sales increased to $506,000 from $489,000 in the fiscal third quarter of 2025, driven by higher sales across the distribution network. The company recorded a net loss of $624,000 for the quarter, compared to a net loss of $580,000 in the same period last year. Net loss per share was $(0.01) for both periods.
For the nine months ended April 30, 2026, net product sales grew to $1,656,000 from $1,435,000 in the prior year, attributed to higher sales across the end-user network. The net loss for the nine-month period narrowed to $1,873,000 from $2,067,000 in the comparable prior-year period. Net loss per share for the nine months was $(0.02) for both years.
Operational Highlights
Jeff Kitchell, President, stated that fiscal year-over-year sales have continued to grow while operating expenses have been reduced. The company introduced new products such as PURE Clean and expanded into the dairy industry through a membrane treatment program. AJ Bogan, Director of Technical Services, is scheduled to present at the Membrane Technology Forum on June 16, 2026. The company also noted growth in the transportation sector with the introduction of PURE Fleet Wash.
Management and Board Changes
Robert Bartlett announced plans to retire from the position of Chief Executive Officer on July 31, 2026. He will remain a Board Member and serve as an Advisor to the CEO. The Board appointed Jeff Kitchell to take over as CEO effective August 1, 2026; he will also become a Board Member. Additionally, Bernard Blotner will leave the Board of Directors.
Financial Results
| Metric | Nine Months Ended April 30, 2026 | Nine Months Ended April 30, 2025 | Three Months Ended April 30, 2026 | Three Months Ended April 30, 2025 |
|---|---|---|---|---|
| Net product sales | $1,656,000 | $1,435,000 | $506,000 | $489,000 |
| Total revenue | $1,658,000 | $1,438,000 | $506,000 | $491,000 |
| Gross profit | $957,000 | $835,000 | $269,000 | $283,000 |
| Net loss | $(1,873,000) | $(2,067,000) | $(624,000) | $(580,000) |
| Net loss per share | $(0.02) | $(0.02) | $(0.01) | $(0.01) |
How will the leadership transition from Robert Bartlett to Jeff Kitchell impact the company's strategic direction?
What are the revenue projections for the newly launched PURE Clean product and the dairy membrane treatment program?
Can the reduction in operating expenses be sustained while scaling the distribution network?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
